2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 202

Analysis of Provider-to-Provider Variability in the Use of Biologics: Data from the Rheumatology Informatics System for Effectiveness Registry

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 455

Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 439

Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 386

Analysis of the Effectiveness of Immunization with Pneumococcal Polysaccharide Vaccine in Children with Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

9:00AM-11:00AM: Abstract Number: 685

Anti-C1q Antibodies and Disease Activity in a Multi-Ethnic Lupus Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 480

ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 486

Anti-Citrullinated Protein Antibody Reactivities in Treatment NaïVe Early Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 397

Anti-Fractalkine Monoclonal Antibody Ameliorates Joint Destruction in Collagen-Induced Arthritis Model through Suppression of Osteoclast Precursor Cell Survival and Migration

Rheumatoid Arthritis – Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 571

Anti-Modified Protein Antibody Response Pattern in Primary Sjögren’s Syndrome: Clinical and Prognostic Implications

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 562

Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 483

Anti-Peptidylarginine Deiminase-4 Antibodies Are Present in the Sputum of RA Patients and Can Activate Peptidylarginine Deiminase-4 Enzyme Activity

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1

Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 16

Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 708

Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 684

ANTI-RO52 KDa and ANTI-RO60 KDa Analysis in Systemic LUPUS Erythematous Patients to Detect ANTI-RO False-Negatives

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].